Intravitreal chemotherapy for vitreous seeding in retinoblastoma: Recent advances and perspectives.

Détails

Ressource 1Télécharger: BIB_D87A68948AC2.P001.pdf (445.21 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_D87A68948AC2
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Intravitreal chemotherapy for vitreous seeding in retinoblastoma: Recent advances and perspectives.
Périodique
Saudi Journal of Ophthalmology : Official Journal of the Saudi Ophthalmological Society
Auteur(s)
Munier F.L., Gaillard M.C., Balmer A., Beck-Popovic M.
ISSN
1319-4534 (Print)
ISSN-L
1319-4534
Statut éditorial
Publié
Date de publication
2013
Peer-reviewed
Oui
Volume
27
Numéro
3
Pages
147-150
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish
Résumé
For decades intravitreal chemotherapy (IViC) remained virtually banished from the therapeutic armamentarium against retinoblastoma, except as a heroic attempt of salvage before enucleation in only eyes with refractory vitreous seeding. Very recently, we have initiated a reappraisal of this route of administration by (1) profiling eligibility criteria, (2) describing a safety-enhanced injection procedure, (3) adjusting the tumoricidal dose of melphalan, and (4) reporting an unprecedented efficacy in terms of tumor control of vitreous seeding. Since then, intravitreal chemotherapy is being progressively implemented worldwide with great success, but still awaits formal validation by the ongoing prospective phase II clinical trial. As far as preliminary results are concerned, IViC appears to achieve complete vitreous response in 100% of the 35 newly recruited patients irrespective of the previous treatment regimen, including external beam radiotherapy and/or intra-arterial melphalan. In other words, vitreous seeding, still considered as the major cause of primary and secondary enucleation, can now be controlled by IViC. However, sterilization of vitreous seeding does not necessarily translate into eye survival, unless the retinal source of the seeds receives concomitant therapy. In conclusion, IViC, an unsophisticated and cost-effective treatment, is about to revolutionize the eye survival prognosis of vitreous disease in advanced retinoblastoma.
Pubmed
Open Access
Oui
Création de la notice
18/11/2013 9:19
Dernière modification de la notice
20/08/2019 15:57
Données d'usage